• Stoke Therapeutics appointed Bo Cumbo to its board.
• Edward Kaye retired as a director; he served on the board since 2017 and was CEO from 2017 to March 2025.
• Cumbo has led rare-disease commercial launches; he is CEO and a director at Solid Biosciences.
• He previously held senior commercial roles at Sarepta Therapeutics, including chief commercial officer, with earlier roles at Vertex and Gilead.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260923239117) on September 23, 2026, and is solely responsible for the information contained therein.